For the Inventor, By the Inventor

Enter assignee name

Inflarx Gmbh

USPTO Granted Patents = 14

CIPO Patents = 1

EPO Patents = 5

Trademarks = 2

Forward Citations = 63

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Renfeng Guo (14 out of 15 patents)

Niels Christoph Riedemann (12 out of 12 patents)

Beifen Shen (4 out of 7 patents)

4. Yan Li (3 out of 307 patents)

5. Yong Li (2 out of 2 patents)

6. Niels R Riedemann (1 out of 1 patent)

7. Niels Cristoph Riedemann (1 out of 1 patent)

8. Yan Li (1 out of 2 patents)

9. Li Yan (0 patent)

10. Yan Li (0 patent)

11. Shen Beifen (0 patent)

14 patents: Sort by Forward Citations

1. 12697351 - METHOD OF TREATING CONDITIONS, REDUCING AN INFLAMMATORY RESPONSE, OR IMPROVING ORGAN FUNCTION IN A SUBJECT HAVING A CORONA VIRUS INFECTION BY ADMINISTERING AN INHIBITOR OF C5A ACTIVITY (2026-08-04),

2. 12180274 - Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity (2024-12-31),

3. 11999698 - Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor (2024-06-04),

4. 11890349 - Treatment of inflammatory diseases with inhibitors of C5A activity (2024-02-06),

5. 11464868 - Treatment of inflammatory diseases with inhibitors of C5A activity (2022-10-11),

6. 11273225 - Treatment of inflammatory diseases with inhibitors of C5a activity (2022-03-15),

7. 11149009 - Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor (2021-10-19),

8. 10858421 - Inhibitors of C5A for the treatment of viral pneumonia (2020-12-08),

9. 10774136 - Anti-C5a binding moieties with high blocking activity (2020-09-15),

10. 10376595 - Treatment of inflammatory diseases with inhibitors of C5a activity (2019-08-13),

11. 10227397 - Inhibitors of C5a for the treatment of viral pneumonia (2019-03-12),

12. 9458233 - Anti-C5a binding moieties with high blocking activity (2016-10-04),

13. 9073983 - Anti-C5A binding moieties with high blocking activity (2015-07-07),

14. 8802096 - Anti-C5a binding antibodies with high block activity (2014-08-12),

Inflarx GmbH is a biopharmaceutical company based in Jena, Germany, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on harnessing its proprietary technology to create monoclonal antibodies that target specific pathways involved in these conditions. With a commitment to advancing medical science, Inflarx aims to address unmet medical needs through its research and development efforts, contributing to improved patient outcomes in the therapeutic landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

14 Patents

#28 in Jena

#2,906 in Germany

#42,199 in the World

Inflarx Gmbh

Forward Citations = 63

8 inventors:

Renfeng Guo (14 out of 15 patents)

Niels Christoph Riedemann (12 out of 12 patents)

Beifen Shen (4 out of 7 patents)

4. Yan Li (3 out of 307 patents)

5. Yong Li (2 out of 2 patents)

Please report any incorrect information to [email protected]

Loading…